CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
July 26, 2018—Leica Biosystems introduced the Bond Rx next-generation research stainer. The new system offers greater flexibility when optimizing conditions for a variety of test types including immunofluorescence, immunohistochemistry, fluorescence in situ hybridization, tyramide signal amplification, multiplexing, and other emerging tests.
Bond Rx allows users to customize dewax options, choose from six probe application and removal protocols, and select the dispense type from three reagent flow options. Reagents are illuminated and provide clear visual alerts, and the version 6.0 software features a highly visual user interface with easy to identify iconography.
“With science advancing at such a rapid rate, it is an exciting time to be supporting researchers as they seek to unlock the complexity of cancer biology and develop new approaches to diagnosis,” Colin White, PhD, global VP of advanced staining, Leica Biosystems, said in a press release. “The release of the next generation of Bond Rx is an important milestone in providing our customers with broader experimental flexibility and improved usability.”